Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center
Advertisement
Articles by Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center
Advertisement
Latest Updated Articles
The Future Treatment Landscape of RCCPublished: December 14th 2020 | Updated:
Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214Published: December 14th 2020 | Updated:
The Biology of RCC and Improved Treatment OutcomesPublished: December 14th 2020 | Updated:
Risk Assessment and Diagnostic Work-upPublished: December 14th 2020 | Updated:
Impact of the Phase 3 CheckMate 9ER Trial on PracticePublished: December 14th 2020 | Updated:
Tumor Biology in Favorable to Poor-Risk RCCPublished: December 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5